Company intelligence / Profile preview

ImmuneMed Inc.

Chuncheon, Gangwon-do, South Koreaimmunemed.net ↗

Ownership: Private
Employees: ~100
Development stage: Phase 2

Overview

The company has developed burfiralimab for Chronic hepatitis B and autoimmune diseases, which has reached Phase 2 clinical trials. Their COVID-19 program with burfiralimab has been discontinued. They also have preclinical programs for Pancreatic Ductal Adenocarcinoma and Graft vs Host Disease.

Therapeutic areas: Metabolic DisordersImmunologyDermatologyOncologyInfectious Diseases
Modalities: Monoclonal antibodyChemical drugsAntiviral cytokine technology
Industry: Biotech

Drug pipeline

1 asset

burfiralimab

Partnerships

Lonza

Beyond the preview

Go deeper on ImmuneMed Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmuneMed Inc..

Explore the full profile